Close mobile menu×
Close mobile menu

Naiyer A. Rizvi, MD

Expertise in: 
Medical Oncology, Lung Cancer, Esophageal Cancer, Cancer Care
Accepting New Patients
Profile Headshot

Appointments

myColumbiaDoctors

For existing patients, login to make an appointment, view documentation or contact your care provider.

Credentials & Experience

Clinical Expertise

  • Lung Cancer
  • Esophageal Cancer
  • Cancer Care
  • Medical Oncology
  • Thoracic Oncology
  • Mesothelioma
  • Immunotherapy

Specialties

Education & Training

  • MD, University of Manitoba Faculty of Medicine (Canada)
  • Residency: University of Manitoba Affiliated Hospital
  • Fellowship: Beth Israel Deaconess Medical Center/Harvard Medical School

About Naiyer Rizvi

Dr. Rizvi is the Price Family Professor of Medicine and Director of Thoracic Oncology as well as Co-Director of Cancer Immunotherapy at Columbia University Irving Medical Center. He is also the Research Director of the Price Family Comprehensive Center for Chest Care at New York-Presbyterian Hospital.

He is an internationally recognized leader in the treatment of lung cancer and immunotherapy drug development. His early clinical trial research played a significant role in the FDA approval of immune checkpoint inhibitors, for melanoma and lung cancer. His research focus is studying mechanisms of sensitivity and resistance to immunotherapy. Through genetic testing of tumors, he has been able to improve the understanding of why immune checkpoint inhibitors work in certain patients and why others do not respond.

He conducts clinical studies of novel immunotherapy drugs and immunotherapy combinations to help more patients in the fight against cancer. He receives funding from the National Institute of Health and Stand Up to Cancer for his research and his work has been published in high impact journals including Science, Nature and New England Journal of Medicine.

Academic Titles

  • Professor of Medicine at CUMC

Hospital Affiliations

  • NewYork-Presbyterian/Columbia
  • NewYork-Presbyterian/Lawrence Hospital

Gender

  • Male

Insurance Accepted

Aetna

  • EPO
  • HMO
  • Medicare Managed Care
  • NY Signature
  • NYP Employee Plan
  • POS
  • PPO
  • Signature Administrators
  • Student Health

Affinity

  • Essential Plan
  • Medicaid Managed Care

Amida Care

  • Special Needs Plan

Cigna

  • EPO
  • Great West
  • HMO
  • POS
  • PPO

Emblem/GHI

  • Medicare Managed Care
  • PPO

Emblem/HIP

  • ConnectiCare
  • EPO
  • Essential Plan
  • HMO
  • Medicaid Managed Care
  • Medicare Managed Care
  • POS
  • PPO
  • Select Care (Exchange)
  • Vytra

Empire Blue Cross Blue Shield

  • Blue Access (Exchange)
  • EPO
  • Gatekeeper (Exchange)
  • HMO
  • Medicare Managed Care
  • Pathway (Exchange)
  • POS
  • PPO

Empire Blue Cross Blue Shield HealthPlus

  • Child/Family Health Plus
  • Essential Plan
  • Medicaid Managed Care

Fidelis Care

  • Child/Family Health Plus
  • Medicaid Managed Care
  • Medicare Managed Care

Healthfirst

  • Child/Family Health Plus
  • Leaf (Exchange)
  • Medicaid Managed Care
  • Medicare Managed Care

Local 1199

  • Local 1199

MagnaCare

  • MagnaCare

Multiplan

  • Multiplan

Oxford Health Plans

  • Freedom
  • Liberty
  • Medicare Managed Care

TRICARE

  • TRICARE

UnitedHealthcare

  • Columbia University Employee Plan
  • Compass (Exchange)
  • Essential Plan
  • HMO
  • Medicaid (Community Plan)
  • Medicare Managed Care
  • POS
  • PPO

VNSNY CHOICE

  • Medicare Managed Care
  • SelectHealth

WellCare

  • Medicaid Managed Care
  • Medicare Managed Care

*Please contact the provider’s office directly to verify that your particular insurance is accepted.

Contact & Locations

1
161 Fort Washington Avenue
New York, New York 10032
Phone:
(212) 305-3997
Fax:
(212) 305-3035
Primary
2
177 Fort Washington Avenue
New York, New York 10032
Phone:
(212) 305-3997

Research

Grants

TOWARDS PRECISION IMMUNOONCOLOGY: UNRAVELING THE GENOMICDETERMINANTS AND MECHANISMS UNDERLYING IMMUNOTHERAPY SENSITIVITY AND RESISTANCE (Federal Gov)

Sep 1 2018 - Aug 31 2025

A PHASE I/II, OPEN-LABEL, TWO PART STUDY OF GSK3359609 IN COMBINATION WITH TREMELIMUMAB IN PARTICIPANTS WITH SELECTED, ADVANCED SOLID TUMORS (P&S Industry Clinical Trial)

Jan 24 2019 - Jan 24 2024

A PHASE II, OPEN LABEL, RANDOMIZED, NON-COMPARATIVE TRIAL OF NIVOLUMAB ALONE OR IN COMBINATION WITH IPILIMUMAB FOR THE TREATMENT OF PATIENTS WITH ADVANCED HYPERMUTATED SOLID TUMORS DETECTED BY A BLOOD BASED ASSAY. (P&S Industry Clinical Trial)

Nov 20 2018 - Nov 20 2023

A RANDOMIZED, PHASE 3, OPEN-LABEL STUDY OF COMBINATIONS OF REGN2810 (ANTI-PD-1 ANTIBODY), PLATINUM-BASED DOUBLET CHEMOTHERAPY, AND IPILIMUMAB (ANTI-CTLA-4 ANTIBODY) VERSUS PEMBROLIZUMAB MONOTHERAPY IN FIRST-LINE TREATMENT OF PATIENTS (P&S Industry Clinical Trial)

Aug 28 2018 - Aug 28 2023

A PHASE I OPEN LABEL STUDY OF GSK3359609 ADMINISTERED ALONE AND IN COMBINATION WITH ANTICANCER AGENTS IN SUBJECTS WITH SELECTED ADVANCED SOLID TUMORS (P&S Industry Clinical Trial)

Jun 22 2018 - Jun 22 2023

AN OPEN-LABEL, MULTI-DRUG, BIOMARKER-DIRECTED, MULTI-CENTRE PHASE II UMBRELLA STUDY IN PATIENTS WITH NON-SMALL CELL LUNG CANCER, WHO PROGRESSED ON AN ANTI-PD-1/PD-L1 CONTAINING THERAPY (HUDSON). (P&S Industry Clinical Trial)

Jun 15 2018 - Jun 15 2023

A PHASE III, DOUBLE-BLINDED, MULTICENTER, RANDOMIZED STUDY EVALUATING THE EFFICACY AND SAFETY OF NEOADJUVANT TREATMENT WITH ATEZOLIZUMAB OR PLACEBO IN COMBINATION WITH PLATINUM-BASED CHEMOTHERAPY IN PATIENTS WITH RESECTABLE STAGE II, IIIA, OR SELECT IIIB (P&S Industry Clinical Trial)

Mar 6 2018 - Mar 6 2023

A PHASE IB/II, OPEN-LABEL, MULTICENTER, RANDOMIZED UMBRELLA STUDY EVALUATING THE EFFICACY AND SAFETY OF MULTIPLE IMMUNOTHERAPY-BASED TREATMENT COMBINATIONS IN PATIENTS WITH METASTATIC NON?SMALL CELL LUNG CANCER (MORPHEUS-LUNG) (P&S Industry Clinical Trial)

Feb 5 2018 - Feb 5 2023

A PHASE 1-2, OPEN-LABEL, DOSE-FINDING, PROOF OF CONCEPT, FIRST-IN-HUMAN STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF CX-2009 IN ADULTS WITH METASTATIC OR LOCALLY ADVANCED UNRESECTABLE SOLID TUMORS (P&S Industry Clinical Trial)

Dec 22 2017 - Dec 22 2022

A MULTICENTER STUDY TO EXPLORE THE MECHANISM OF ACQUIRED IMMUNE ESCAPE IN PATIENTS WITH METASTATIC CANCER PROGRESSING ON CHECKPOINT INHIBITOR THERAPY (P&S Industry Clinical Trial)

Nov 28 2017 - Nov 28 2022

A PHASE 1B, OPEN-LABEL, MULTI-CENTER, DOSE (P&S Industry Clinical Trial)

Oct 30 2017 - Oct 30 2022

AN OPEN-LABEL, DOSE-FINDING AND PROOF OF CONCEPT STUDY OF THE PD-L1 PROBODYTM THERAPEUTIC, CX-072, AS MONOTHERAPY AND IN COMBINATION WITH YERVOY (IPILIMUMAB) OR WITH ZELBORAF (VEMURAFENIB) IN SUBJECTS WITH ADVANCED (P&S Industry Clinical Trial)

Mar 21 2017 - Mar 21 2022

ELUCIDATING GENETICS OF RESPONSE TO IMMUNE CHECKPOINT BLOCKADE IN LUNG CANCER (Federal Gov)

Jan 18 2017 - Dec 31 2021

A PHASE 1/1B, OPEN-LABEL, MULTICENTER, REPEAT-DOSE, DOSE- SELECTION STUDY OF CPI-444 AS SINGLE AGENT AND IN COMBINATION WITH ATEZOLIZUMAB IN PATIENTS WITH SELECTED INCURABLE CANCERS (P&S Industry Clinical Trial)

Jun 20 2016 - Jun 20 2021

A PHASE II, NON-COMPARATIVE, OPEN LABEL, MULTI-CENTRE, INTERNATIONAL STUDY OF MEDI4736, IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER (STAGE IIIB-IV) WHO HAVE RECEIVED AT LEAST TWO PRIOR SYSTEMIC (P&S Industry Clinical Trial)

Mar 24 2015 - Mar 24 2020

PROTOCOL CA209153: A PHASE IIIB/IV SAFETY TRIAL OF NIVOLUMAB (BMS-936558) IN SUBJECTS WITH ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER WHO HAVE PROGRESSED DURING OR AFTER RECEIVING AT LEAST ONE PRIOR SYSTEMIC REGIMEN (P&S Industry Clinical Trial)

Mar 3 2015 - Mar 3 2020

A PHASE I/II DOSE ESCALATION AND COHORT EXPANSION STUDY OF THE SAFETY, TOLERABILITY AND EFFICACY OF ANTI-CD27 ANTIBODY (VARLILUMAB) ADMINISTERED IN COMBINATION WITH ANTI-PD-1 (NIVOLUMAB) IN ADVANCED REFRACTORY SOLID TUMORS (P&S Industry Clinical Trial)

Feb 17 2015 - Feb 17 2020

EVALUATION OF ERLOTIB AS A NEOADJUVANT THERAPY IN STAGE III NSCLC PATIENTS WITH EGFR MUTATIONS (EVENT TRIAL) PROTOCOL (P&S Industry Clinical Trial)

Jul 10 2014 - Jul 10 2019

CHARACTERIZING GENETIC AND IMMUNE PREDICTORS OF RESPONSE TO IMMUNOTHERAPY IN PATIENTS WITH SMALL CELL LUNG CANCER (Private)

Aug 2 2017 - Aug 1 2018

TARGETING KRAS MUTANT LUNG CANCERS (Private)

Aug 1 2015 - Jul 31 2018